Class summary at a glance.

Every drug in the Norepinephrine Reuptake Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $50.5Mcombined across class
Total Rx claims: 514K122K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Atomoxetine

Brand: Strattera · 514K Part D claims (CY24) · 122K beneficiaries · First FDA approval: 2002-11-26

8 generic mfrs 7 plans require PA

Low NADAC$0.406

→

Avg plan cost$1.72

Part D spend $50.5M 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.